ProCE Banner Activity

Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC


Slides from a 2024 live ASCO satellite symposium covering the recent developments in the rapidly evolving landscape of EGFR-mutant NSCLC, including the use of biomarkers for selecting primary therapy, clinical trial, and expert considerations on the latest practice changing results presented at the ASCO annual meeting.

Released: May 29, 2024

Expiration: May 28, 2025



Nicolas Girard

Nicolas Girard, MD, PhD

Chair of Medical Oncology
Head of the Thorax Institute Curie-Montsouris
Institut Curie
Universite Paris-Saclay
Paris, France

Natasha Leighl

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Karen Reckamp

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Clinical Professor, Department of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Boehringer Ingelheim Pharmaceuticals, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC